Total body irradiation (TBI) has been thought to promote donor cell engraftment in allogeneic High-TBI-(>8Gy), Low-TBI-( 8Gy), and no-TBI-myeloablative conditioning (MAC), and Low-TBIand no-TBI-reduced-intensity conditioning (RIC). In both MUD and MMUD, neutrophil engraftment rate was >90% in each of the five conditioning groups, and TBI was not associated with prompt neutrophil engraftment in multivariate analyses. Conversely, in CBT, TBI regimens had a higher rate of day-30 neutrophil engraftment than no-TBI-regimens: 78% in High-TBI-MAC, 83%
| I N T R O D U C T I O N
Allogeneic hematopoietic cell transplantation (HCT) has been developed as a curative treatment for hematological malignancies. HCT recipients will frequently experience various adverse events, and all of them initially have to achieve donor cell engraftment during the first month following HCT to acquire an allogeneic anti-leukemia/lymphoma effect.
Historically, allogeneic HCT has spread widely since the initial success of high-dose total body irradiation (TBI) with cyclophosphamide (CY) 50-year ago. Since then, TBI with CY has been the standard myeloablative conditioning (MAC) regimen. 1 Conversely, a higher dose of irradiation has been shown to result in increased organ toxicities, [2] [3] [4] [5] although it was also linked to a reduced risk of leukemia relapse. 1, 6 Therefore, to reduce the adverse toxicities due to TBI, clinical investigators have explored alternative strategies including no-TBI or reduced-intensity conditioning (RIC). However, these strategies might raise a concern of graft failure in an unrelated transplant or HLAmismatched transplant setting due to insufficient immunosuppression, as reported in early studies. 1, [7] [8] [9] [10] Therefore, TBI has been widely incorporated into conditioning regimens because of its theoretical potential to suppress recipient-side immunity and prevent graft rejection, in addition to enhanced anti-leukemic effects. However, recent progress with conditioning strategies, donor source selection algorithms, graftversus-host disease (GVHD) prophylaxis, and various approaches to supportive care may improve sustained engraftment even in these alternative HCT settings. To the best of our knowledge, there have been no reports in large cohorts that comprehensively assessed the impact of TBI on neutrophil engraftment in the setting of unrelated HCT as a primary endpoint.
Thus, the impact of TBI on neutrophil engraftment following HCT from an unrelated bone marrow (BMT) or cord blood donor was retrospectively analyzed using a Japanese transplant registry database. First, the impact of TBI on cumulative neutrophil engraftment was analyzed in each donor cohort. Next, we evaluated the effects of TBI in subgroups of the unrelated cord blood transplantation (CBT) stratified according to conditioning intensity, number of HLA-matches, and the presence of anti-HLA antibodies.
| P A T I E NT S A ND M E T H O DS

| Definitions of categories
Neutrophil engraftment was defined as the first of three sequential days when the neutrophil count was >500 3 10 Other regimens were classified as RIC. Most CBT patients (n 5 1437, >98%) received single cord blood. The /kg in the CBT group. G-CSF was used in >90%
recipients for all types of donors.
The details of the patient distributions among the conditioning types are shown in Supporting Information Tables S1 and S2, according to the individual donor cohorts (MUD, MMUD, and CBT) and conditioning intensity (MAC and RIC). In the MAC group, High-TBI regimens were frequently used for younger recipients (<50 y.o.) and those with ALL in any donor cohort (Supporting Information Table S1 ). There was no difference in infused cell doses among the conditioning types (Novs. Low-vs. High-TBI-MAC) in any donor cohort. In the RIC group, there was no difference in age, infused cell dose or G-CSF usage between conditioning types in any donor cohort (Supporting Information Table S2 ).
| Neutrophil engraftment in the overall MUD, MMUD, and CBT cohorts
Overall neutrophil engraftment at 30 days post-HCT was 96% (95%CI:
95%-97%), 95% (95%CI: 94%-96%), and 77% (95%CI: 74%-79%) in the MUD, MMUD, and CBT cohorts, respectively.
In the MUD cohort, there was no difference in engraftment achievement among the types of conditioning in a univariate analysis (P 5 .34, Figure 1A ), and more than 95% of recipients could achieve Table S3 ).
Conversely, in the CBT cohort, the probabilities of neutrophil engraftment at 30 days post-HCT were significantly higher in TBI-regimens: 78% (95%CI: 75%-81%) in High-TBI-MAC, 83% (95%CI: 74%-89%) in Low-TBI-MAC, and 76% (95%CI: 72%-80%) in Low-TBI-RIC versus 65% (95%CI: 53%-75%) in No-TBI-MAC, and 68% (95%CI:
56%-77%) in No-TBI-RIC (P < .001, Figure 1A Table S3 ).
When we separately analyzed the impact of TBI in the MAC and RIC sub-cohorts, TBI had a favorable impact on neutrophil engraftment in the CBT cohort, but not in the MUD or MMUD cohort ( Figure 1B ).
In summary, TBI did not have a favorable impact on successful neutrophil engraftment in unrelated BMT. Conversely, in the CBT cohort, TBI had a significantly favorable effect on neutrophil engraftment in both the MAC and RIC groups. Therefore, in subsequent analyses, we explored the significance of incorporating TBI into conditioning regimens, with a particular focus on the CBT sub-cohorts stratified according to HLA match, infused cell dose, and the presence of anti-HLA antibody.
| Subgroup analyses according to HLA allelematch and conditioning intensity in the CBT cohort
In the CBT sub-cohorts with a 6/6 or 5/6 HLA allele-match between the donor and recipient, there was no difference in neutrophil engraftment among the conditioning types in the MAC or RIC groups ( In summary, when CBT with low doses of infused TNC or CD34-positive cells was selected, TBI seemed to have a favorable effect on neutrophil engraftment only in specific MAC regimens.
| Subgroup analyses in CBT recipients with anti-HLA antibodies
Furthermore, we analyzed the impact of TBI in recipients who had detectable anti-HLA antibodies prior to HCT, which is also considered to be a risk factor for graft rejection. [16] [17] [18] Since only 173 recipients were reported to have anti-HLA antibodies, we analyzed the impact of High-TBI, Low-TBI, and No-TBI without grouping according to the conditioning intensity (Figure 3 ). Multivariate analysis suggested that the use of TBI was significantly associated with increased neutrophil engraftment [HR of High-TBI: 2Á4 (95%CI: 1Á2-4Á9), P 5 .02; HR of Low-TBI: 2Á2 (95%CI: 1Á2-4Á3), P 5 .02]. In summary, the use of TBI might enhance neutrophil engraftment even in recipients with anti-HLA antibodies.
| Impact of TBI on other outcomes in HCT from MUD, MMUD, and CBT
Although the primary endpoint of this study was neutrophil engraftment, the impact of TBI on other outcomes was also assessed (Supporting Information Figure S3 ). In the CBT cohort, TBI-regimens tended to be associated with a lower risk of non-relapse mortality.
| DISCUSSION
This is the first study to comprehensively assess the impact of TBI on Table S3 ), although the actual engraftment probabilities were fairly similar in a univariate analysis ( Figure 1A ). While the reason for this result is still unclear, damage to the marrow environment due to High-TBI-MAC may eventually result in impaired engraftment, as recently reported. 20 In summary, the addition of TBI as well as an increased conditioning intensity might be unnecessary to achieve neutrophil engraftment in the recent practice of unrelated BMT.
Conversely, in the CBT cohort, TBI still seems to be necessary for prompt neutrophil engraftment and may be more critical than the This study has several limitations due to its retrospective nature.
The selection of the conditioning regimens and the use of TBI are usually based on several clinical factors, including age, disease, and disease risk. Therefore, there might be some selection preference or bias due to the various patient backgrounds. As most CBT used single cord blood in this cohort, other registry studies are necessary to address whether the impact of TBI differ between single and double CBT.
However, the use of a large cohort revealed that TBI had different impacts on neutrophil engraftment according to the donor types, and made it possible to identify which recipients may benefit from the use of TBI in CBT.
In conclusion, TBI-regimens had no impact on neutrophil engraftment in the current practice of unrelated BMT from MUD or MMUD.
However, TBI is still necessary to enhance engraftment in CBT, regardless of the conditioning intensity. Especially, recipients who receive CBT with two or more HLA-allele mismatches or with anti-HLA antibodies may benefit from the addition of TBI to the conditioning regimen. Further observational analyses from other large registry databases would be warranted before we can reach definitive conclusions regarding the use of TBI. In addition, even if we used TBI, the probability of neutrophil engraftment was lower in CBT compared with the other BMT. Therefore, further investigation to enhance overall engraftment achievement in CBT is still equired. 
